Foghorn Therapeutics (Foghorn Therapeutics) EBIT : $-102.78 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Foghorn Therapeutics EBIT?

Foghorn Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-28.19 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-102.78 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Foghorn Therapeutics's annualized ROC % for the quarter that ended in Mar. 2024 was -126.39%. Foghorn Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -269.68%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Foghorn Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -56.78%.

Foghorn Therapeutics EBIT Historical Data

The historical data trend for Foghorn Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Foghorn Therapeutics EBIT Chart

Foghorn Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-50.59

-67.82

-99.41

-117.14

-107.91

Foghorn Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-33.32	-32.05	-17.08	-25.46	-28.19

Competitive Comparison of Foghorn Therapeutics's EBIT

For the Biotechnology subindustry, Foghorn Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Foghorn Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Foghorn Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Foghorn Therapeutics's EV-to-EBIT falls into.

Foghorn Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-102.78 Mil.

Foghorn Therapeutics (NAS:FHTX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Foghorn Therapeutics's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-112.776 * ( 1 - 0% )	/	( (93.186	+	85.272)	/ 2 )
=	-112.776	/	89.229
=	-126.39 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	285.916	-	10.985	-	( 234.057	-	max(0, 58.436	-	240.181	+	234.057	))
=	93.186

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	255.004	-	10.277	-	( 206.661	-	max(0, 52.065	-	211.52	+	206.661	))
=	85.272

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Foghorn Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-112.776	/	( ( (42.912 + max(-43.794, 0))	+	(40.724 + max(-38.538, 0)) )	/	2 )
=	-112.776	/	( ( 42.912	+	40.724 )	/	2 )
=	-112.776	/	41.818
=	-269.68 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	6.124)	-	(10.985	+	34.55	+	4.383)
=	-43.794

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	4.859)	-	(10.277	+	31.501	+	1.619)
=	-38.538

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Foghorn Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-102.783	/	181.016
	=	-56.78 %

Foghorn Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Foghorn Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Foghorn Therapeutics (Foghorn Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Foghorn Therapeutics Inc (NAS:FHTX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Technology Square, Suite 700, Cambridge, MA, USA, 02139

Website

https://www.foghorntx.com

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Executives

Alfonso Quintas Cardama	officer: Chief Medical Officer	C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Samuel Agresta	officer: Chief Medical Officer	784 MEMORIAL DR., CAMBRIDGE MA 02139
Lynch Thomas J. Jr.	director	800 HOWARD AVENUE, YALE PHYSICIANS BUILDING, 2ND FLOOR, NEW HAVEN CT 06519
B Lynne Parshall	director	2855 GAZELLE COURT, CARLSBAD CA 92010
Carlos Costa	officer: Chief People Officer	C/O FOGHORN THERAPEUTICS INC., 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Fanny Cavalie	officer: Chief Strategy/Bus Ops Officer	C/O FOGHORN THERAPEUTICS INC., 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Ian F Smith	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Michael Lacascia	officer: Chief Legal Officer	500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Carl Decicco	officer: Chief Scientific Officer	100 BINNEY STREET, SUITE 610, CAMBRIDGE MA 02142
Flagship Ventures Opportunities Fund I General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Abu Dhabi Investment Authority	10 percent owner	211 CORNICHE STREET, PO BOX 3600, ABU DHABI C0 0000
Michael Mendelsohn	director	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Adam Koppel	director	C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Steven F. Bellon	officer: See Remarks	500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Jose Baselga	director	780 MEMORIAL DRIVE, CAMBRIDGE MA 02139